ATM and familial pancreatic carcinoma: Thus, albeit highly efficient in Atm-null pancreatic cancer cells, the sole FOLFIRINOX treatment selects for more aggressive subclones, which can be partly erased by the following PAD maintenance treatment, an in vitro observation supporting our in vivo data.